Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed HER2-negative adenocarcinoma of the breast
Locally advanced (Stage 3B) or metastatic (Stage 4) disease
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
Received up to 2 prior chemotherapy regimens (not including neoadjuvant/adjuvant therapy) for advanced or metastatic disease
Participants with hormone-receptor positive tumors must have failed available lines of hormonal therapy unless hormone therapy was not tolerated or not clinically appropriate
≥ 2 weeks elapsed from the completion of previous treatment regimen and must have recovered or be at a new stable baseline from any related toxicities
Radiographically measurable or evaluable disease
An mGPS of 1 or 2 as defined below:
* Criteria:
1. modified Glasgow prognostic score (mGPS) of 1: CRP \> 10 mg/L and albumin ≥ 35 g/L
2. mGPS of 2: C-reactive protein (CRP) \> 10 mg/L and albumin \< 35 g/L
You may not be if
Received prior treatment with capecitabine or fluoropyrimidine for advanced or metastatic disease
Received more than 2 prior regimens for advanced or metastatic disease (not including hormonal therapy in the metastatic setting or neoadjuvant or adjuvant therapies)
Unknown hormone-receptor status
Ongoing radiation therapy or radiation therapy administered within 2 weeks of enrollment
Concurrent anticancer therapy
Inadequate renal, hepatic or bone marrow function
Another current or previous malignancy within 2 years of study entry unless approved by the sponsor
Clareo Health | A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
